InVivo Therapeutics Announces Publication of CONTEMPO Registry Study Data in Peer-Reviewed Journal Spinal Cord
July 16 2019 - 08:00AM
Business Wire
InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV) today
announced the publication of a manuscript in the peer-reviewed
journal Spinal Cord describing its CONTEMPO registry study data.
The CONTEMPO registry study, part of the Company’s IDE submission
for the Neuro-Spinal Scaffold™, was designed to provide
comprehensive natural history benchmarks for the Neuro-Spinal
Scaffold™ clinical study results. The CONTEMPO study included
neurological recovery data from three registries of spinal cord
injury (SCI) patients with similar baseline characteristics to
those in the INSPIRE 1.0 Study. The registries included the North
American Clinical Trials Network (NACTN), European Multicenter
Study about Spinal Cord Injury (EMSCI), and Spinal Cord Injury
Model Systems. A total of 170 patients were included from the three
registries, including 12 individuals from NACTN, 64 from EMSCI, and
94 from Model Systems. AIS conversion rates at approximately six
months post-injury varied from 16.7% - 23.4% (21.1% weighted
average) across the three registries.
Richard Toselli, M.D., InVivo’s President and Chief Executive
Officer, said, “We are pleased to see the findings from the
CONTEMPO registry study published in this peer-reviewed journal,
and we are satisfied that the findings continue to support our
understanding of the natural history of these acute SCI
patients.”
The publication is now available electronically at:
https://www.nature.com/articles/s41393-019-0299-8.
About InVivo Therapeutics
InVivo Therapeutics Holdings Corp. is a research and
clinical-stage biomaterials and biotechnology company with a focus
on treatment of spinal cord injuries. The company was founded in
2005 with proprietary technology co-invented by Robert Langer,
Sc.D., Professor at Massachusetts Institute of Technology, and
Joseph P. Vacanti, M.D., who then was at Boston Children’s Hospital
and who now is affiliated with Massachusetts General Hospital. The
publicly traded company is headquartered in Cambridge, MA. For more
details, visit www.invivotherapeutics.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190716005054/en/
IR CONTACT: Bret Shapiro, Managing Partner CORE IR Phone:
(516) 222-2560 brets@coreir.com MEDIA CONTACT: Jules Abraham
CORE IR Phone: (917) 885-7378 julesa@coreir.com
InVivo Therapeutics (NASDAQ:NVIV)
Historical Stock Chart
From Feb 2024 to Mar 2024
InVivo Therapeutics (NASDAQ:NVIV)
Historical Stock Chart
From Mar 2023 to Mar 2024